

## Investor News

**Markus Georgi**  
Senior Vice President  
Investor Relations & Sustainability

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2485  
F +49 6172 608-2488  
markus.georgi@fresenius.com  
www.fresenius.com

July 8, 2020

### **Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged**

Fresenius will hold its Annual General Meeting (AGM) on August 28, 2020 as a virtual event. Originally, the AGM was scheduled for May 20, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at €0.84 per share entitled to a dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius will include further details in the AGM invitation that is to be published in the Federal Gazette (*Bundesanzeiger*) and on the corporate website in July.

# # #

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2019, Group sales were €35.4 billion. On March 31, 2020, the Fresenius Group had 299,594 employees worldwide.

For more information visit the Company's website at [www.fresenius.com](http://www.fresenius.com).  
Follow us on Twitter: [www.twitter.com/fresenius\\_ir](https://www.twitter.com/fresenius_ir).

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to

certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg, HRB 11852  
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg, HRB 11673  
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey,  
Mats Henriksson, Rice Powell, Dr. Ernst Wastler  
Chairman of the Supervisory Board: Dr. Gerd Krick